Capella

Capella—the Online Voice of Progress in RNAi

Alnylam welcomes you to Capella, the destination for updates on our progress in translating the science of RNAi into innovative medicines. For Alnylam, Capella is our online voice for communicating the scientific progress we are making as we work to develop innovative medicines for patients.

To view our corporate presentation, click here.

We hosted a series of online “RNAi Roundtables” in August and September, at which Alnylam scientists, clinical collaborators, and patients or patient advocates reviewed recent progress in many of the company’s late-stage pipeline programs and discussed the related disease areas.

(more…)

We presented additional pre-clinical data further elucidating fitusiran’s novel mechanism of action at the International Society of Thrombosis and Haemostasis (ISTH) Congress, held July 8 – 13, 2017 in Berlin, Germany.

Presentation on the development of a PK-PD model of fitusiran

Presentation on measurement of thrombin generation in conditions of low antithrombin

View the presentation on the use of bypassing agents in the context of antithrombin reduction

 

We presented pre-clinical data with ALN-F12 at the International Society of Thrombosis and Haemostasis (ISTH) Congress, held July 8 – 13, 2017 in Berlin, Germany. Data showed that reduction of hepatic factor XII (FXII) expression in mice by ALN-F12 inhibits thrombosis without increasing bleeding risk. We believe that reduction of plasma FXII by ALN-F12 represents a promising approach for the prophylactic treatment of thrombosis.

View the presentation

(more…)

We reported new positive results from our ongoing Phase 2 open-label extension (OLE) study with fitusiran in patients with hemophilia A and B, with or without inhibitors, at the International Society of Thrombosis and Haemostasis (ISTH) Congress, held July 8 – 13, 2017 in Berlin, Germany.

Read our press release

View the complete Phase 2 OLE data presentation

(more…)

SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.